Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 2, 2017, Pages 149-156

  Maneiro, José Ramón ^a   Souto, Alejandro ^a   Gomez Reino, Juan J ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Biological disease modifying antirheumatic drugs; JAK inhibitors; Malignancies; Tofacitinib

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; CANCER INCIDENCE; CANCER RISK; DRUG EFFICACY; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; MELANOMA; META ANALYSIS; NON MELANOMA SKIN CANCER; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SOLID MALIGNANT NEOPLASM; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; NEOPLASM; NETWORK META-ANALYSIS; RISK;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; HUMANS; NEOPLASMS; NETWORK META-ANALYSIS; PIPERIDINES; PYRIMIDINES; PYRROLES; RISK;

EID: 85015706868     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.02.007     Document Type: Article

References (38)

1. Singh, J.A., Christensen, R., Wells, G.A., Suarez-Almazor, M.E., Buchbinder, R., Lopez-Olivo, M.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can Med Assoc J. 181 (2009), 787–796, 10.1503/cmaj.091391.
2. OʼDell, J.R., Mikuls, T.R., Taylor, T.H., Ahluwalia, V., Brophy, M., Warren, S.R., et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369 (2013), 307–318, 10.1056/NEJMoa1303006.
3. Meyer, D.M., Jesson, M.I., Li, X., Elrick, M.M., Funckes-Shippy, C.L., Warner, J.D., et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond), 7, 2010, 41, 10.1186/1476-9255-7-411476-9255-7-41 [pii].
4. Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460, 10.1016/s0140-6736(12)61424-x.
5. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507, 10.1056/NEJMoa1109071.
6. Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386, 10.1056/NEJMoa1310476.
7. Salgado, E., Maneiro, J.R., Carmona, L., Gomez-Reino, J.J., Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 73 (2014), 871–882, 10.1136/annrheumdis-2012-203116 [pii].
8. Souto, A., Salgado, E., Maneiro, J.R., Mera, A., Carmona, L., Gomez-Reino, J.J., Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67 (2015), 117–127, 10.1002/art.38894.
9. Lopez-Olivo, M.A., Tayar, J.H., Martinez-Lopez, J.A., Pollono, E.N., Cueto, J.P., Gonzales-Crespo, M.R., et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. Jama 308 (2012), 898–908, 10.1001/2012.jama.10857.
10. Thompson, A.E., Rieder, S.W., Pope, J.E., Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63 (2011), 1479–1485, 10.1002/art.30310.
11. Mariette, X., Matucci-Cerinic, M., Pavelka, K., Taylor, P., van Vollenhoven, R., Heatley, R., et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70 (2011), 1895–1904, 10.1136/ard.2010.149419.
12. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 295 (2006), 2275–2285, 10.1001/jama.295.19.2275.
13. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100, 10.1371/journal.pmed.1000100.
14. Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011. Available from: www.cochrane-handbook.org. [updated March 2011; accessed February 12. 2015].
15. OCEBM Levels of Evidence Working Group. Levels of Evidence of Oxford Centre for Evidence-Based Medicine. Available from: http://www.cebm.net/index.aspx?o=5653; 2011 [accessed February 12, 2015].
16. Puhan, M.A., Schunemann, H.J., Murad, M.H., Li, T., Brignardello-Petersen, R., Singh, J.A., et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. Br Med J., 349, 2014, g5630, 10.1136/bmj.g5630.
17. Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D.M., Higgins, J.P., Evaluating the quality of evidence from a network meta-analysis. PloS One., 9, 2014, e99682, 10.1371/journal.pone.0099682.
18. Bradburn, M.J., Deeks, J.J., Berlin, J.A., Russell Localio, A., Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 26 (2007), 53–77, 10.1002/sim.2528.
19. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials. 7 (1986), 177–188.
20. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. Br Med J. 327 (2003), 557–560, 10.1136/bmj.327.7414.557.
21. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. Br Med J. 315 (1997), 629–634.
22. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med. 21 (2002), 1539–1558, 10.1002/sim.1186.
23. White, I., Multivariate random-effects meta-analysis. Stata J. 9 (2009), 40–56.
24. White, I.R., Barrett, J.K., Jackson, D., Higgins, J.P., Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 3 (2012), 111–125, 10.1002/jrsm.1045.
25. Turner, R.M., Davey, J., Clarke, M.J., Thompson, S.G., Higgins, J.P., Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41 (2012), 818–827, 10.1093/ije/dys041.
26. Chaimani, A., Salanti, G., Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 3 (2012), 161–176, 10.1002/jrsm.57.
27. Miyasaka, N., Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 18 (2008), 252–262, 10.1007/s10165-008-0045-0.
28. Emery, P., Breedveld, F., van der Heijde, D., Ferraccioli, G., Dougados, M., Robertson, D., et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 62 (2010), 674–682, 10.1002/art.27268.
29. Abasolo, L., Judez, E., Descalzo, M.A., Gonzalez-Alvaro, I., Jover, J.A., Carmona, L., et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 37 (2008), 388–397, 10.1016/j.semarthrit.2007.08.006.
30. Mercer, L.K., Lunt, M., Low, A.L., Dixon, W.G., Watson, K.D., Symmons, D.P., et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 74 (2015), 1087–1093, 10.1136/annrheumdis-2013-204851.
31. Curtis, J.R., Lee, E.B., Kaplan, I.V., Kwok, K., Geier, J., Benda, B., et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-205847.
32. Mellemkjaer, L., Linet, M.S., Gridley, G., Frisch, M., Moller, H., Olsen, J.H., Rheumatoid arthritis and cancer risk. Eur J Cancer 32A (1996), 1753–1757.
33. Zink, A., Askling, J., Dixon, W.G., Klareskog, L., Silman, A.J., Symmons, D.P., European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 68 (2009), 1240–1246, 10.1136/ard.2008.091926.
34. Askling, J., Baecklund, E., Granath, F., Geborek, P., Fored, M., Backlin, C., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68 (2009), 648–653, 10.1136/ard.2007.085852.
35. Askling, J., van Vollenhoven, R.F., Granath, F., Raaschou, P., Fored, C.M., Baecklund, E., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 60 (2009), 3180–3189, 10.1002/art.24941.
36. Mercer, L.K., Green, A.C., Galloway, J.B., Davies, R., Lunt, M., Dixon, W.G., et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71 (2012), 869–874, 10.1136/annrheumdis-2011-200622.
37. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm304199.pdf.
38. Curtis, J.R., Zhang, R., Krishnaswami, S., Anisfeld, A., Chen, Y., Strengholt, S., et al. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib. Clin Rheumatol, 2016, 10.1007/s10067-016-3359-x.